MCID: GST060
MIFTS: 53

Gastric Cancer, Somatic malady

Categories: Genetic diseases (common), Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Gastric Cancer, Somatic

About this section

Aliases & Descriptions for Gastric Cancer, Somatic:

Name: Gastric Cancer, Somatic 49 11 22
Malignant Neoplasm of Stomach 65
Gastric Cancer Intestinal 67
Stomach Carcinoma 65
 
Gastric Cancer 67
Stomach Cancer 67
Gasc 67

Characteristics:

HPO:

61
gastric cancer, somatic:
Inheritance: somatic mutation


Classifications:



External Ids:

OMIM49 613659
MeSH36 D013274
ICD1027 C16

Summaries for Gastric Cancer, Somatic

About this section
UniProtKB/Swiss-Prot:67 Gastric cancer: A malignant disease which starts in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. The term gastric cancer or gastric carcinoma refers to adenocarcinoma of the stomach that accounts for most of all gastric malignant tumors. Two main histologic types are recognized, diffuse type and intestinal type carcinomas. Diffuse tumors are poorly differentiated infiltrating lesions, resulting in thickening of the stomach. In contrast, intestinal tumors are usually exophytic, often ulcerating, and associated with intestinal metaplasia of the stomach, most often observed in sporadic disease.

MalaCards based summary: Gastric Cancer, Somatic, also known as malignant neoplasm of stomach, is related to gastric cancer risk after h. pylori infection and stomach cancer, and has symptoms including stomach cancer, gastrointestinal gas and nausea and vomiting. An important gene associated with Gastric Cancer, Somatic is MUTYH (MutY DNA Glycosylase), and among its related pathways are Angiogenesis and VEGF Pathway (Tocris). Affiliated tissues include lung, breast and colon, and related mouse phenotypes are muscle and no phenotypic analysis.

OMIM:49 In a review article on the genetic predisposition to gastric cancer, Bevan and Houlston (1999) concluded that several... (613659) more...

Related Diseases for Gastric Cancer, Somatic

About this section

Diseases related to Gastric Cancer, Somatic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 66)
idRelated DiseaseScoreTop Affiliating Genes
1gastric cancer risk after h. pylori infection32.3CDH1, KRAS
2stomach cancer12.4
3familial stomach cancer12.2
4stomach cancer, childhood12.0
5atypical mole syndrome10.6APC, MUTYH
6breast ductal adenoma10.6CDH1, ERBB2
7familial congenital fourth cranial nerve palsy10.5APC, CDH1, MUTYH
8nasal cavity squamous cell carcinoma10.5CDH1, ERBB2
9cataract-intellectual disability-hypogonadism syndrome10.4KRAS, MUTYH
10gyrate atrophy of choroid and retina with or without ornithinemia10.4ERBB2, FGFR2
11breast granular cell tumor10.3CDH1, ERBB2
12megalencephaly-capillary malformation-polymicrogyria syndrome, somatic10.3MUT, PIK3CA
13cowden syndrome 510.3MUT, PIK3CA
14spermatogenic failure 610.3MUT, PIK3CA
15gastric cardia carcinoma10.3CDH1, ERBB2
16myh9-related disorders10.2APC, KRAS, MUTYH
17pars planitis10.2IRF1, NEU1
18intracranial sinus thrombosis10.2CDH1, KRAS
19ulnar neuropathy10.2APC, KRAS, MUTYH
20acute retinal necrosis syndrome10.2ERBB2, PIK3CA
21organ system benign neoplasm10.2APC, KRAS, MUTYH
22common variable immunodeficiency10.2APC, KRAS, MUTYH
23ehlers-danlos syndrome, type viic10.2APC, GLUL
24congenital disorder of glycosylation, type if10.2ERBB2, NEU1
25anterior horn cell disease10.1KRAS, PIK3CA
26tubular adenocarcinoma10.1CDH1, FGFR2, KRAS
27diffuse idiopathic pulmonary neuroendocrine cell hyperplasia10.1CDH1, ERBB2, KRAS
28hartnup disorder10.1CDH1, ERBB2, KRAS
29hereditary congenital ptosis10.1KRAS, MUTYH
30pancreatic somatostatinoma10.1CDH1, ERBB2, KRAS
31estrogen-receptor negative breast cancer10.1ERBB2, FGFR2, PIK3CA
32brachyolmia10.1CDH1, ERBB2, KRAS
33proctitis10.0CDH1, ERBB2, KRAS
34gastric cancer10.0
35biliary tract neoplasm10.0APC, CDH1, KRAS, MUTYH
36restless legs syndrome10.0APC, CDH1, KRAS, MUTYH
37zimmermann-laband syndrome 210.0CDH1, ERBB2, PIK3CA
38chondromalacia patellae10.0CDH1, ERBB2, KRAS
39eccrine papillary adenocarcinoma9.9ERBB2, KRAS, PIK3CA
40neuromuscular disease9.9ERBB2, KRAS, PIK3CA
41cavernous hemangioma9.9ERBB2, KRAS, PIK3CA
42desmoid disease, hereditary9.9APC, GLUL, MUTYH
43head and neck carcinoma9.8ERBB2, KRAS
44epidermal nevus, somatic9.8KRAS, MUT, PIK3CA
45non-invasive bladder urothelial carcinoma9.8APC, KRAS, MUTYH
46cervical cancer, somatic9.8CDH1, ERBB2, FGFR2, KRAS
47placental insufficiency9.8APC, KRAS, MUTYH, PIK3CA
48gastritis9.7
49ovary epithelial cancer9.7CDH1, ERBB2, KRAS, PIK3CA
50ovarian wilms' cancer9.7CDH1, ERBB2, KRAS, PIK3CA

Graphical network of the top 20 diseases related to Gastric Cancer, Somatic:



Diseases related to gastric cancer, somatic

Symptoms for Gastric Cancer, Somatic

About this section


Clinical features from OMIM:

613659

HPO human phenotypes related to Gastric Cancer, Somatic:

id Description Frequency HPO Source Accession
1 stomach cancer HP:0012126

UMLS symptoms related to Gastric Cancer, Somatic:


gastrointestinal gas, nausea and vomiting, heartburn, dyspepsia, diarrhea, constipation, abdominal pain

Drugs & Therapeutics for Gastric Cancer, Somatic

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)15 Company Approval Date
1
Cyramza15 41 RAMUCIRUMAB Eli Lilly April 2014
FDA Label: Cyramza
Disease/s that Drug Treats:gastric cancer
Indications and Usage:15 CYRAMZA® is a human vascular endothelial growth factor receptor 2antagonist indicated as a single agent or in combination with paclitaxel, for treatmentof advanced gastric or gastro-esophageal junctionadenocarcinoma, with disease progression on or after priorfluoropyrimidine- or platinum-containing chemotherapy. (1.1) in combination with docetaxel, for treatment of metastatic nonsmallcell lung cancer with disease progression on or afterplatinum-based chemotherapy. Patients with EGFR or ALKgenomic tumor aberrations should have disease progression onFDA-approved therapy for these aberrations prior to receivingCYRAMZA. (1.2) in combination with FOLFIRI, for the treatment of metastaticcolorectal cancer with disease progression on or after priortherapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.(1.3)
DrugBank Targets: -
Mechanism of Action:15 
Target: ligand-stimulated activation of VEGF Receptor 2
Action: inhibitor
FDA: Ramucirumab is a vascular endothelial growth factor receptor 2 antagonist that specifically binds VEGF Receptor2 and blocks binding of VEGFR ligands, VEGF-A, VEGF-C, and VEGF-D. As a result, ramucirumab inhibits ligandstimulatedactivation of VEGF Receptor 2, thereby inhibiting ligand-induced proliferation, and migration of humanendothelial cells. Ramucirumab inhibited angiogenesis in an in vivo animal model.
2
Herceptin15 41 TRASTUZUMAB Genentech October 1998
FDA Label: Herceptin
Disease/s that Drug Treats:Breast cancer/gastric cancer
Indications and Usage:15 Herceptin is a HER2/neu receptor antagonist indicated for: the treatment of HER2 overexpressing breast cancer (1.1, 1.2). the treatment of HER2-overexpressing metastatic gastric orgastroesophageal junction adenocarcinoma (1.3)
DrugBank Targets:13 1. Receptor tyrosine-protein kinase erbB-2;2. Epidermal growth factor receptor;3. Complement C1r subcomponent;4. Complement C1q subcomponent subunit A;5. Complement C1q subcomponent subunit B;6. Complement C1q subcomponent subunit C;7. Complement C1s subcomponent;8. High affinity immunoglobulin gamma Fc receptor I;9. Low affinity immunoglobulin gamma Fc region receptor II-a;10. Low affinity immunoglobulin gamma Fc region receptor II-b;11. Low affinity immunoglobulin gamma Fc region receptor II-c;12. Low affinity immunoglobulin gamma Fc region receptor III-B;13. Low affinity immunoglobulin gamma Fc region receptor III-A
Mechanism of Action:15 
Target: human epidermal growth factor receptor 2 protein (HER2)
Action: binds with strong affinity for immune response
FDA: The HER2 (or c-erbB2) proto-oncogene encodes a transmembrane receptor protein of 185 kDa, which is structurally related to the epidermal growth factor receptor. Herceptin has been shown, in both in vitro assays and in animals, to inhibit the proliferation of human tumor cells that overexpress HER2. Herceptin is a mediator of antibody-dependent cellular cytotoxicity (ADCC). In vitro, Herceptin-mediated ADCC has been shown to be preferentially exerted on HER2 overexpressing cancer cells compared with cancer cells that do not overexpress HER2.
3
Iressa15 41 GEFITINIB AstraZeneca May 2003
FDA Label: Iressa
Disease/s that Drug Treats:Non-Small-Cell Lung Cancer
Indications and Usage:15 IRESSA is indicated as monotherapy for the continued treatment of patients with locally advanced ormetastatic non-small cell lung cancer after failure of both platinum-based and docetaxelchemotherapies who are benefiting or have benefited from IRESSA.In light of positive survival data with other agents including another oral EGFR inhibitor, physiciansshould use other treatment options in advanced non-small cell lung cancer patient populations whohave received one or two prior chemotherapy regimens and are refractory or intolerant to their mostrecent regimen. The effectiveness of IRESSA was initially based on objective response rates (see CLINICALPHARMACOLOGY-Clinical Studies section). Subsequent studies intended to demonstrate anincrease in survival have been unsuccessful. Specifically, results from a large placebo-controlledrandomized trial in patients with advanced NSCLC who progressed while receiving or within 90 daysof the last dose of chemotherapy or were intolerant to the most recent prior chemotherapy regimen, didnot show an improvement in survival (see CLINICAL PHARMACOLOGY- Clinical Studiessection).Results from two large, controlled, randomized trials in first-line treatment of non-small cell lungcancer showed no benefit from adding IRESSA to doublet, platinum-based chemotherapy.
DrugBank Targets:13 1. Epidermal growth factor receptor
Mechanism of Action:15 
Target: EGFR tyrosine kinase and other tyrosine kinases
Action: inhibitor
FDA: The mechanism of the clinical antitumor action of gefitinib is not fully characterized. Gefitinibinhibits the intracellular phosphorylation of numerous tyrosine kinases associated with transmembranecell surface receptors, including the tyrosine kinases associated with the epidermal growth factorreceptor (EGFR-TK). EGFR is expressed on the cell surface of many normal cells and cancer cells.No clinical studies have been performed that demonstrate a correlation between EGFR receptorexpression and response to gefitinib.
4
Iressa15 GEFITINIB AstraZeneca May 2003
FDA Label: Iressa
Disease/s that Drug Treats:Non-Small-Cell Lung Cancer
Indications and Usage:15 IRESSA is indicated as monotherapy for the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies who are benefiting or have benefited from IRESSA. In light of positive survival data with other agents including another oral EGFR inhibitor, physicians should use other treatment options in advanced non-small cell lung cancer patient populations who have received one or two prior chemotherapy regimens and are refractory or intolerant to their most recent regimen. The effectiveness of IRESSA was initially based on objective response rates (see CLINICAL PHARMACOLOGY-Clinical Studies section). Subsequent studies intended to demonstrate an increase in survival have been unsuccessful. Specifically, results from a large placebo-controlled randomized trial in patients with advanced NSCLC who progressed while receiving or within 90 days of the last dose of chemotherapy or were intolerant to the most recent prior chemotherapy regimen, did not show an improvement in survival (see CLINICAL PHARMACOLOGY- Clinical Studies section). Results from two large, controlled, randomized trials in first-line treatment of non-small cell lung cancer showed no benefit from adding IRESSA to doublet, platinum-based chemotherapy.
DrugBank Targets:13 Epidermal growth factor receptor
Mechanism of Action:15 
Target: EGFR tyrosine kinase
Action: inhibitor
FDA: The mechanism of the clinical antitumor action of gefitinib is not fully characterized. Gefitinib inhibits the intracellular phosphorylation of numerous tyrosine kinases associated with transmembrane cell surface receptors, including the tyrosine kinases associated with the epidermal growth factor receptor (EGFR-TK). EGFR is expressed on the cell surface of many normal cells and cancer cells. No clinical studies have been performed that demonstrate a correlation between EGFR receptor expression and response to gefitinib.

Drugs for Gastric Cancer, Somatic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
RucaparibPhase 1, Phase 2109931954
Synonyms:
AG-014699
 
AG014699
PF-01367338
rucaparib
2Poly(ADP-ribose) Polymerase InhibitorsPhase 1, Phase 2250

Interventional clinical trials:

idNameStatusNCT IDPhase
1A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)RecruitingNCT01482715Phase 1, Phase 2
2A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA MutationActive, not recruitingNCT02042378Phase 2

Search NIH Clinical Center for Gastric Cancer, Somatic

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Gastric Cancer, Somatic cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Gastric Cancer, Somatic:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Gastric Cancer, Somatic:
Tumor infiltrating lymphocytes, PMIDs: 24329789, 19342963, 23904171, 21498393, 22996367, 19304471, 22555974, 15800326, 23650429, 21325070, 24218514, 8170938, 12242449

Genetic Tests for Gastric Cancer, Somatic

About this section

Genetic tests related to Gastric Cancer, Somatic:

id Genetic test Affiliating Genes
1 Gastric Cancer, Somatic22 KRAS, FGFR2

Anatomical Context for Gastric Cancer, Somatic

About this section

MalaCards organs/tissues related to Gastric Cancer, Somatic:

33
Lung, Breast, Colon, Lymph node, Small intestine, Endothelial, Prostate

Animal Models for Gastric Cancer, Somatic or affiliated genes

About this section

MGI Mouse Phenotypes related to Gastric Cancer, Somatic:

38 (show all 21)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053698.5APC, ERBB2, FGFR2, KRAS, NEU1, PIK3CA
2MP:00030128.2APC, CDH1, FGFR2, KRAS, NEU1, PIK3CA
3MP:00053888.2CTNNBIP1, ERBB2, FGFR2, KRAS, MUT, NEU1
4MP:00053708.0APC, FGFR2, GLUL, KLF6, KRAS, MUT
5MP:00053898.0APC, CDH1, ERBB2, FGFR2, KLF6, KRAS
6MP:00028737.9APC, CDH1, ERBB2, FGFR2, GLUL, IRF1
7MP:00053677.9APC, CTNNBIP1, FGFR2, IRF1, KRAS, MUT
8MP:00020067.9APC, CDH1, ERBB2, FGFR2, IRF1, KRAS
9MP:00053807.6APC, CDH1, CTNNBIP1, ERBB2, FGFR2, KLF6
10MP:00053907.5APC, CTNNBIP1, ERBB2, FGFR2, IRF1, KRAS
11MP:00053817.5APC, CDH1, CTNNBIP1, ERBB2, FGFR2, KRAS
12MP:00107717.3APC, CDH1, ERBB2, FGFR2, IRF1, KLF6
13MP:00053797.2APC, CDH1, ERBB2, FGFR2, IRF1, KLF6
14MP:00036316.7APC, CTNNBIP1, ERBB2, FGFR2, GLUL, KRAS
15MP:00053876.6APC, CDH1, FGFR2, IRF1, KRAS, MUT
16MP:00053856.2APC, CDH1, ERBB2, FGFR2, IRF1, KLF6
17MP:00053766.0APC, CDH1, ERBB2, FGFR2, GLUL, IRF1
18MP:00053785.5APC, CDH1, CTNNBIP1, ERBB2, FGFR2, GLUL
19MP:00053845.3APC, CDH1, CTNNBIP1, ERBB2, FGFR2, GLUL
20MP:00107685.1APC, CDH1, CTNNBIP1, ERBB2, FGFR2, GLUL

Publications for Gastric Cancer, Somatic

About this section

Variations for Gastric Cancer, Somatic

About this section

UniProtKB/Swiss-Prot genetic disease variations for Gastric Cancer, Somatic:

67 (show all 17)
id Symbol AA change Variation ID SNP ID
1APCp.Gly817CysVAR_005035
2APCp.Ile880ThrVAR_005036
3APCp.Asn942AspVAR_005039
4APCp.Gly1120GluVAR_005042rs28933379
5APCp.Arg1171HisVAR_005043
6APCp.Phe1197SerVAR_005045
7APCp.Ile1259ThrVAR_005046
8APCp.Gly1312GluVAR_005050
9APCp.Val1326AlaVAR_005052
10CASP10p.Met147ThrVAR_037428rs121909776
11IRF1p.Met8LeuVAR_065134
12IRF1p.Trp11ArgVAR_065135
13KRASp.Gly12ValVAR_006840
14KRASp.Ala59ThrVAR_016030
15KRASp.Lys5AsnVAR_064849
16MUTYHp.Pro402SerVAR_026049
17MUTYHp.Gln411ArgVAR_026050

Clinvar genetic disease variations for Gastric Cancer, Somatic:

5 (show all 17)
id Gene Variation Type Significance SNP ID Assembly Location
1CDH1NM_004360.4(CDH1): c.2494G> A (p.Val832Met)single nucleotide variantLikely pathogenic, Pathogenicrs35572355GRCh37Chr 16, 68867247: 68867247
2KRASNM_033360.3(KRAS): c.35G> A (p.Gly12Asp)single nucleotide variantPathogenicrs121913529GRCh37Chr 12, 25398284: 25398284
3KRASNM_033360.3(KRAS): c.34G> A (p.Gly12Ser)single nucleotide variantPathogenicrs121913530GRCh37Chr 12, 25398285: 25398285
4TP53NM_000546.5(TP53): c.847C> T (p.Arg283Cys)single nucleotide variantLikely pathogenicrs149633775GRCh37Chr 17, 7577091: 7577091
5FGFR2NM_000141.4(FGFR2): c.799T> C (p.Ser267Pro)single nucleotide variantPathogenicrs121918505GRCh37Chr 10, 123279633: 123279633
6PIK3CANM_006218.2(PIK3CA): c.3140A> G (p.His1047Arg)single nucleotide variantPathogenicrs121913279GRCh37Chr 3, 178952085: 178952085
7PIK3CANM_006218.2(PIK3CA): c.1633G> A (p.Glu545Lys)single nucleotide variantPathogenicrs104886003GRCh37Chr 3, 178936091: 178936091
8PIK3CANM_006218.2(PIK3CA): c.3203dupA (p.Asn1068Lysfs)duplicationPathogenicrs587776802GRCh37Chr 3, 178952148: 178952148
9ERBB2NM_001005862.2(ERBB2): c.2236G> A (p.Gly746Ser)single nucleotide variantPathogenicrs28933369GRCh37Chr 17, 37880997: 37880997
10IRF1NM_002198.2(IRF1): c.22A> T (p.Met8Leu)single nucleotide variantPathogenicrs121912469GRCh37Chr 5, 131825149: 131825149
11MUTYHNM_001128425.1(MUTYH): c.1213C> T (p.Pro405Ser)single nucleotide variantPathogenicrs121908382GRCh37Chr 1, 45797202: 45797202
12MUTYHNM_001128425.1(MUTYH): c.1241A> G (p.Gln414Arg)single nucleotide variantPathogenicrs121908383GRCh37Chr 1, 45797174: 45797174
13KLF6NM_001300.5(KLF6): c.465C> A (p.Ser155Arg)single nucleotide variantPathogenicrs121909144GRCh37Chr 10, 3824044: 3824044
14CASP10NM_032977.3(CASP10): c.769C> T (p.Gln257Ter)single nucleotide variantPathogenicrs121909775GRCh37Chr 2, 202070652: 202070652
15CASP10NM_032977.3(CASP10): c.440T> C (p.Met147Thr)single nucleotide variantPathogenicrs121909776GRCh37Chr 2, 202052521: 202052521
16APCNM_000038.5(APC): c.3359G> A (p.Gly1120Glu)single nucleotide variantPathogenicrs28933379GRCh37Chr 5, 112174650: 112174650
17APCNM_000038.5(APC): c.3199C> T (p.Gln1067Ter)single nucleotide variantPathogenicrs137854571GRCh37Chr 5, 112174490: 112174490

Cosmic variations for Gastric Cancer, Somatic:

7 (show top 50)    (show all 350)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Conf
1COSM476BRAFstomach,NS,carcinoma,adenocarcinoma7
2COSM516KRASstomach,NS,carcinoma,adenocarcinoma7
3COSM517KRASstomach,NS,carcinoma,adenocarcinoma7
4COSM520KRASstomach,NS,carcinoma,adenocarcinoma7
5COSM521KRASstomach,NS,carcinoma,adenocarcinoma7
6COSM522KRASstomach,NS,carcinoma,adenocarcinoma7
7COSM527KRASstomach,NS,carcinoma,adenocarcinoma7
8COSM528KRASstomach,NS,carcinoma,adenocarcinoma7
9COSM532KRASstomach,NS,carcinoma,adenocarcinoma7
10COSM534KRASstomach,NS,carcinoma,adenocarcinoma7
11COSM549KRASstomach,NS,carcinoma,adenocarcinoma7
12COSM569NRASstomach,NS,carcinoma,adenocarcinoma7
13COSM580NRASstomach,NS,carcinoma,adenocarcinoma7
14COSM685ERBB2stomach,NS,carcinoma,adenocarcinoma7
15COSM746PIK3CAstomach,NS,carcinoma,adenocarcinoma7
16COSM760PIK3CAstomach,NS,carcinoma,adenocarcinoma7
17COSM763PIK3CAstomach,NS,carcinoma,adenocarcinoma7
18COSM764PIK3CAstomach,NS,carcinoma,adenocarcinoma7
19COSM767PIK3CAstomach,NS,carcinoma,adenocarcinoma7
20COSM769PIK3CAstomach,NS,carcinoma,adenocarcinoma7
21COSM775PIK3CAstomach,NS,carcinoma,adenocarcinoma7
22COSM5140PTENstomach,NS,carcinoma,adenocarcinoma7
23COSM5151PTENstomach,NS,carcinoma,adenocarcinoma7
24COSM5172PTENstomach,NS,carcinoma,adenocarcinoma7
25COSM5205PTENstomach,NS,carcinoma,adenocarcinoma7
26COSM5278PTENstomach,NS,carcinoma,adenocarcinoma7
27COSM5279PTENstomach,NS,carcinoma,adenocarcinoma7
28COSM5280PTENstomach,NS,carcinoma,adenocarcinoma7
29COSM5330PTENstomach,NS,carcinoma,adenocarcinoma7
30COSM5662CTNNB1stomach,NS,carcinoma,adenocarcinoma7
31COSM5664CTNNB1stomach,NS,carcinoma,adenocarcinoma7
32COSM5668CTNNB1stomach,NS,carcinoma,adenocarcinoma7
33COSM5670CTNNB1stomach,NS,carcinoma,adenocarcinoma7
34COSM5671CTNNB1stomach,NS,carcinoma,adenocarcinoma7
35COSM5672CTNNB1stomach,NS,carcinoma,adenocarcinoma7
36COSM5679CTNNB1stomach,NS,carcinoma,adenocarcinoma7
37COSM5703CTNNB1stomach,NS,carcinoma,adenocarcinoma7
38COSM5704CTNNB1stomach,NS,carcinoma,adenocarcinoma7
39COSM5733CTNNB1stomach,NS,carcinoma,adenocarcinoma7
40COSM5738CTNNB1stomach,NS,carcinoma,adenocarcinoma7
41COSM5743CTNNB1stomach,NS,carcinoma,adenocarcinoma7
42COSM6815TP53stomach,NS,carcinoma,adenocarcinoma7
43COSM6906TP53stomach,NS,carcinoma,adenocarcinoma7
44COSM6932TP53stomach,NS,carcinoma,adenocarcinoma7
45COSM10647TP53stomach,NS,carcinoma,adenocarcinoma7
46COSM10648TP53stomach,NS,carcinoma,adenocarcinoma7
47COSM10651TP53stomach,NS,carcinoma,adenocarcinoma7
48COSM10654TP53stomach,NS,carcinoma,adenocarcinoma7
49COSM10656TP53stomach,NS,carcinoma,adenocarcinoma7
50COSM10659TP53stomach,NS,carcinoma,adenocarcinoma7

Expression for genes affiliated with Gastric Cancer, Somatic

About this section
Search GEO for disease gene expression data for Gastric Cancer, Somatic.

Pathways for genes affiliated with Gastric Cancer, Somatic

About this section

Pathways related to Gastric Cancer, Somatic according to GeneCards Suite gene sharing:

(show all 30)
idSuper pathwaysScoreTop Affiliating Genes
19.8FGFR2, PIK3CA
2
Show member pathways
9.4CASP10, KRAS, PIK3CA
3
Show member pathways
9.4ERBB2, FGFR2, KRAS
49.4IRF1, KRAS, PIK3CA
5
Show member pathways
9.3ERBB2, KRAS, PIK3CA
6
Show member pathways
9.3ERBB2, KRAS, PIK3CA
79.3CDH1, PIK3CA
89.3CDH1, PIK3CA
9
Show member pathways
9.2CASP10, IRF1, KRAS, PIK3CA
10
Show member pathways
9.2APC, ERBB2, FGFR2, KRAS
119.1APC, CASP10, CDH1
129.1APC, FGFR2, KRAS, PIK3CA
13
Show member pathways
9.1APC, FGFR2, KRAS, PIK3CA
149.1APC, ERBB2, KRAS, PIK3CA
15
Show member pathways
9.1ERBB2, IRF1, KRAS, PIK3CA
169.1CASP10, CDH1, ERBB2
179.0ERBB2, FGFR2, KRAS, PIK3CA
189.0CDH1, FGFR2, PIK3CA
199.0APC, CDH1, KRAS
208.9CDH1, ERBB2, PIK3CA
218.9CDH1, ERBB2, KRAS
228.9APC, CDH1, CTNNBIP1
238.8APC, CASP10, ERBB2, KRAS, PIK3CA
24
Show member pathways
8.8CASP10, ERBB2, FGFR2, KRAS, PIK3CA
25
Show member pathways
8.8APC, ERBB2, FGFR2, KRAS, PIK3CA
26
Show member pathways
8.5CDH1, ERBB2, KRAS, PIK3CA
27
Show member pathways
8.3APC, CDH1, ERBB2, KRAS, PIK3CA
28
Show member pathways
8.3APC, CDH1, ERBB2, KRAS, PIK3CA
29
Show member pathways
8.2CDH1, ERBB2, FGFR2, KRAS, PIK3CA
308.0APC, CDH1, ERBB2, FGFR2, KRAS, PIK3CA

GO Terms for genes affiliated with Gastric Cancer, Somatic

About this section

Cellular components related to Gastric Cancer, Somatic according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1lateral plasma membraneGO:00163289.4APC, CDH1

Biological processes related to Gastric Cancer, Somatic according to GeneCards Suite gene sharing:

(show all 7)
idNameGO IDScoreTop Affiliating Genes
1regulation of multicellular organism growthGO:004001410.1FGFR2, PIK3CA
2regulation of ERK1 and ERK2 cascadeGO:007037210.1ERBB2, FGFR2
3cellular component disassembly involved in execution phase of apoptosisGO:000692110.0APC, CDH1
4ERBB2 signaling pathwayGO:00381289.8ERBB2, KRAS, PIK3CA
5fibroblast growth factor receptor signaling pathwayGO:00085439.4ERBB2, FGFR2, KRAS, PIK3CA
6insulin receptor signaling pathwayGO:00082869.3ERBB2, FGFR2, KRAS, PIK3CA
7innate immune responseGO:00450878.8CASP10, ERBB2, FGFR2, KRAS, PIK3CA

Molecular functions related to Gastric Cancer, Somatic according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1gamma-catenin bindingGO:00452959.4APC, CDH1

Sources for Gastric Cancer, Somatic

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet